Mitsubishi Tanabe Pharma America, Inc. (MTPA) announced the 48-week results from a global, multi-center, open-label, Phase 3 clinical trial (MT-1186-A01) evaluating the long-term safety and tolerability of RADICAVA ORS (edaravone) in the treatment of amyotrophic lateral sclerosis (ALS). Data from the study showed that RADICAVA ORS was generally well tolerated during the treatment period, with no new safety signals identified. “We’re encouraged by the data that we continue to co...